At least 15 biotechs and pharmas are slated to report earnings this week. Five companies - Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Ranbaxy Laboratories Ltd. (NSE:RANBAXY; BSE:500359), Santarus Inc. (NASDAQ:SNTS), SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) and Spectrum Pharmaceuticals Inc (NASDAQ:SPPI) - are expected to post an increase in 2Q12 EPS of more than 25% on top-line growth. 2Q12 revenues for specialty pharma Jazz are projected to increase by 94% to $125.5 million, while revenues for